BE-101

Small molecule

BBe Biopharma

BE-101 is one of 20 small molecule programs targeting Hemophilia B. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophilia BActive, not recruiting

Hemophilia BPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Hemophilia B

#DrugCompanyPhaseTrials

Recombinant Factor IX Coagulation

Pfizer

Approved

2 2

IB1001

MMedexus Pharma, Inc.

Phase 3

3 3

Translarna

BENEFIX

6 5

Recombinant Factor IX

BBaxalta now part of Shire

Phase 3

1 6

Rfix

Pfizer

Phase 3

3 7

Factor Ix

CSL Behring

Phase 3

3 8

Nonacog Alfa

Pfizer

Phase 3

3 9

Rix-FP

CSL Behring

Phase 3

3 10

Rfixfc

BBioverativ Therapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Hemophilia B

NCT06611436

Clinical

Trials by Indication[1]

Hemophilia B1 trial

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Recruiting·BBe Biopharma·Phase 1/2·NCT06611436·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BE-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BE-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BE-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Be Biopharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBe Biopharma

BE-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hemophilia B1 trial

References

Drug Info

Quick Facts

Related News